.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,559,158

« Back to Dashboard
Patent 6,559,158 protects RELISTOR and is included in two NDAs. There have been three Paragraph IV challenges on Relistor.

This patent has seven patent family members in six countries.

Summary for Patent: 6,559,158

Title: Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
Abstract:A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
Inventor(s): Foss; Joseph F. (Chicago, IL), Roizen; Michael F. (Chicago, IL), Moss; Jonathan (Chicago, IL), Yuan; Chun-Su (Chicago, IL), Drell; William (San Diego, CA)
Assignee: UR Labs, Inc. (Reno, NV) The University of Chicago (Chicago, IL)
Application Number:09/669,358
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 22nd percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Salix Pharms
RELISTOR
methylnaltrexone bromide
SOLUTION;SUBCUTANEOUS021964-002Sep 27, 2010RXYes6,559,158► subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION
Salix Pharms
RELISTOR
methylnaltrexone bromide
SOLUTION;SUBCUTANEOUS021964-001Apr 24, 2008RXYes6,559,158► subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYes6,559,158► subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,559,158

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,608,075 Use of methylnaltrexone and related compounds► subscribe
5,972,954 Use of methylnaltrexone and related compounds► subscribe
6,274,591 Use of methylnaltrexone and related compounds► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,559,158

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria467415► subscribe
Australia1380299► subscribe
Australia758416► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc